Last Updated: November 16, 2026

ALPROLIX Drug Profile

« Back to Dashboard


Summary for Tradename: ALPROLIX
High Confidence Patents:27
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for ALPROLIX
Recent Clinical Trials for ALPROLIX

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Bioverativ Therapeutics Inc.Early Phase 1
Emory UniversityEarly Phase 1
Novo Nordisk A/SPhase 1

See all ALPROLIX clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ALPROLIX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ALPROLIX Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Bioverativ Therapeutics, Inc. ALPROLIX coagulation factor ix (recombinant), fc fusion protein For Injection 125444 10,030,045 2036-10-17 DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc. ALPROLIX coagulation factor ix (recombinant), fc fusion protein For Injection 125444 10,058,480 2033-07-03 DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc. ALPROLIX coagulation factor ix (recombinant), fc fusion protein For Injection 125444 10,113,000 2036-08-01 DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc. ALPROLIX coagulation factor ix (recombinant), fc fusion protein For Injection 125444 10,253,075 2035-02-26 DrugPatentWatch analysis and company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for ALPROLIX Derived from Patent Text Search

No patents found based on company disclosures

ALPROLIX Market Dynamics, Financial Trajectory, Patent Exclusivity, and Competitive Outlook

Last updated: September 8, 2026

ALPROLIX, or eftrenonacog alfa, is a long-acting recombinant factor IX Fc fusion protein for hemophilia B. Sanofi markets the product after acquiring Bioverativ in 2018. Its commercial value rests on reduced infusion frequency, established physician use, and the need for lifelong replacement therapy. Growth is now constrained by competing extended-half-life products, hemophilia B gene therapies, payer controls, and the approaching end of U.S. biologic exclusivity.

What is ALPROLIX and how does it work?

ALPROLIX is a recombinant coagulation factor IX linked to the Fc portion of human immunoglobulin G1. The Fc fusion extends circulation time through the neonatal Fc receptor recycling pathway.

The FDA approved ALPROLIX on March 28, 2014, for adults and children with hemophilia B caused by congenital factor IX deficiency. Approved uses include:

  • Routine prophylaxis to prevent or reduce bleeding episodes
  • On-demand treatment and control of bleeding
  • Perioperative management

The product is administered intravenously. The label provides weight-based regimens for routine prevention and episodic treatment. Dose selection depends on the patient’s age, clinical response, bleeding severity, and recovery of factor IX activity.[1]

ALPROLIX is not a small-molecule drug and does not have a traditional Orange Book exclusivity profile. It is licensed as a biologic under section 351(a) of the Public Health Service Act. Patent and exclusivity analysis therefore relies on the Purple Book, FDA biologics records, USPTO assignments, BPCIA litigation, and international patent registers rather than the conventional Orange Book framework.[2]

What is the commercial history of ALPROLIX?

ALPROLIX was developed by Biogen and later commercialized by Bioverativ, the hemophilia-focused company spun out of Biogen in 2017. Sanofi acquired Bioverativ in 2018 for approximately $11.6 billion, gaining ALPROLIX, ELOCTATE, and the broader hemophilia franchise.[3]

Bioverativ reported the following ALPROLIX net revenues before the Sanofi acquisition:

Fiscal year ALPROLIX net revenue
2015 Approximately $294 million
2016 Approximately $371 million
2017 Approximately $460 million

The revenue trajectory reflected increasing adoption of extended-half-life factor IX therapy and conversion from conventional recombinant factor IX products. Growth was supported by prophylaxis demand, home infusion, and the product’s reduced dosing burden compared with standard half-life factor IX.[4]

After the acquisition, Sanofi integrated ALPROLIX into its rare blood disorders portfolio. Sanofi’s public reporting has not maintained the same level of historical product-level disclosure in every reporting period, making direct year-by-year global comparisons less consistent than during Bioverativ’s standalone reporting period. The commercial direction remains clear: ALPROLIX is a mature, cash-generating hemophilia product rather than a high-growth launch asset.

How does ALPROLIX generate revenue?

ALPROLIX revenue is driven by treatment duration, prophylaxis penetration, dosing frequency, and reimbursement access.

Patients with severe hemophilia B often require lifelong factor replacement. This produces recurring demand, but annual revenue per patient varies substantially by:

  • Body weight
  • Baseline factor IX activity
  • Bleeding phenotype
  • Prophylaxis schedule
  • Adherence
  • Use of home infusion
  • Payer contracting
  • National tender pricing
  • Switching to gene therapy or another extended-half-life product

The product’s commercial proposition is lower infusion frequency. A longer half-life can reduce administration burden and, in some patients, lower annual factor consumption. That creates a tension between patient convenience and supplier revenue: clinical efficiency can reduce units sold even when market penetration rises.

The largest revenue exposure remains the United States, where factor replacement products command high prices and specialty pharmacy distribution is well established. European markets generally impose stronger price controls, health technology assessment requirements, and centralized procurement. Emerging markets add volume potential but carry lower net prices and greater reimbursement limitations.

How does ALPROLIX compare with competing hemophilia B products?

ALPROLIX competes across three treatment categories: conventional factor IX replacement, extended-half-life factor IX products, and gene therapy.

Product Active technology Company Commercial position
ALPROLIX Factor IX-Fc fusion Sanofi Established extended-half-life replacement therapy
BENEFIX Recombinant factor IX Pfizer Standard-half-life incumbent
RIXUBIS Recombinant factor IX Takeda Standard-half-life factor IX
IXINITY Recombinant factor IX Medexus Standard-half-life competitor
REBINYN GlycoPEGylated factor IX Novo Nordisk Extended-half-life replacement
IDELVION Albumin-fused recombinant factor IX CSL Behring Extended-half-life replacement
HEMGENIX AAV-based gene therapy CSL Behring One-time treatment approach
BEQVEZ AAV-based gene therapy Pfizer One-time treatment approach, FDA approved in 2024

ALPROLIX’s principal product-level competitors are IDELVION and REBINYN. Their differentiation is based on half-life, dosing intervals, clinical familiarity, pediatric use, inhibitor management, supply reliability, and payer contracts.

Gene therapies change the market structure. HEMGENIX was approved by the FDA in November 2022, and BEQVEZ was approved in April 2024. These therapies may reduce long-term demand for factor IX in eligible adults, but their uptake is constrained by high upfront prices, durability questions, liver-directed administration, eligibility criteria, clinical infrastructure, and payer authorization.[5][6]

When does ALPROLIX lose exclusivity?

ALPROLIX’s U.S. biologic exclusivity period generally runs for 12 years from the date of first licensure under the Biologics Price Competition and Innovation Act. Based on the March 28, 2014 FDA approval date, statutory reference-product exclusivity would generally extend to March 2026.[1][7]

That date does not automatically produce generic or biosimilar entry. A biosimilar applicant must obtain FDA approval through the 351(k) pathway, demonstrate high similarity and no clinically meaningful differences, and resolve patent barriers. The actual commercial entry date may occur after statutory exclusivity if patents, litigation, manufacturing constraints, or regulatory review delay launch.

International timing differs. European and other jurisdictions apply their own data, market, supplementary protection certificate, and patent rules. European exclusivity may not align with the U.S. March 2026 date.

What patents protect ALPROLIX?

The ALPROLIX patent estate is built around biologic composition, Fc-fusion architecture, production, purification, formulations, and therapeutic use. Relevant patent families may cover:

  • Recombinant factor IX-Fc molecules
  • Nucleic acids encoding the fusion protein
  • Host cells and expression systems
  • Cell-culture and manufacturing processes
  • Purification and viral-clearance methods
  • Stable liquid or lyophilized formulations
  • Treatment and prophylaxis methods
  • Dosing regimens for hemophilia B

The original development and commercial rights trace to Biogen and Bioverativ, with Sanofi becoming the principal commercial owner through the Bioverativ acquisition. Patent ownership can vary by family and jurisdiction because assignments, continuations, divisionals, and co-owned rights may be recorded separately.

A complete freedom-to-operate analysis requires reviewing individual U.S., European, and national patent registers, including continuation status and terminal disclaimers. The product’s legal protection is not represented by a single patent expiration date. For biologics, the practical entry barrier is the combined effect of patent families, manufacturing know-how, regulatory comparability, and litigation strategy.

What is the Orange Book and Purple Book status of ALPROLIX?

ALPROLIX is not analyzed as a conventional Orange Book-listed chemical drug. The FDA’s Purple Book is the relevant source for licensed biological products, reference-product status, biosimilar applications, and interchangeability information.[2]

As a biologic approved under a full 351(a) license, ALPROLIX can face biosimilar competition through the 351(k) pathway. A biosimilar applicant may rely on the reference product’s regulatory package while conducting comparative analytical, pharmacokinetic, pharmacodynamic, and, where necessary, clinical studies.

A biosimilar approval would not necessarily make the product interchangeable. Interchangeability requires additional statutory and FDA requirements and may affect pharmacy substitution, payer treatment, and contracting dynamics.

Are there Paragraph IV challenges to ALPROLIX?

Paragraph IV certification applies primarily to small-molecule products filed under the abbreviated new drug application pathway. It is not the standard mechanism for challenging a licensed biologic such as ALPROLIX.

For ALPROLIX, the relevant pathway is a biosimilar application under section 351(k), followed by potential patent litigation under the BPCIA. A biosimilar applicant may challenge patents through the BPCIA patent-exchange process and related declaratory or infringement actions.

No publicly prominent U.S. BPCIA litigation involving an approved ALPROLIX biosimilar had materially reshaped the market through mid-2024. The absence of a major reported challenge reduces near-term legal disruption but does not eliminate future biosimilar risk.

What litigation and settlement risks affect ALPROLIX?

The principal legal risks are:

  1. Biosimilar patent litigation after a 351(k) filing
  2. Challenges to composition-of-matter or fusion-protein claims
  3. Invalidity attacks against formulation and manufacturing claims
  4. Patent-term disputes involving continuations and terminal disclaimers
  5. Contract and license disputes affecting manufacturing or regional commercialization

No major publicly disclosed settlement agreement has established a market-wide ALPROLIX biosimilar entry date through mid-2024. If Sanofi reaches a future settlement, the key commercial terms would likely include an agreed entry date, license scope, patent releases, supply rights, and possible restrictions on interchangeable substitution.

How strong is the ALPROLIX patent estate?

The patent estate is commercially meaningful but faces the normal aging profile of a product first approved in 2014.

Its strongest defenses are likely to be:

  • Complex biologic manufacturing
  • Specialized factor IX-Fc analytics
  • Multiple process and formulation layers
  • Regulatory burden for biosimilar development
  • High clinical and manufacturing costs
  • Limited number of potential competitors

Its weaker points are:

  • The approaching end of the 12-year U.S. reference-product exclusivity period
  • Potential invalidity challenges to narrow or later-filed claims
  • The absence of a conventional small-molecule patent barrier
  • Increasing clinical and economic competition from gene therapy
  • Potential switching by patients who achieve sustained factor expression

Manufacturing know-how may remain more important than any individual patent. Biosimilar developers must reproduce a highly characterized glycoprotein fusion molecule and demonstrate consistent activity, purity, aggregate control, immunogenicity profile, and stability.

What generic or biosimilar entry scenarios exist?

Three entry scenarios are commercially plausible.

Scenario 1: Delayed biosimilar entry

A biosimilar is approved after March 2026 but launches later because of patent litigation or a negotiated settlement. This would preserve a substantial portion of ALPROLIX revenue into the late 2020s.

Scenario 2: Limited biosimilar erosion

One or more biosimilars enter, but payer contracts and physician familiarity limit switching. Revenue declines gradually rather than collapsing. Sanofi may defend volume through contracting, patient services, and geographic pricing.

Scenario 3: Combined biosimilar and gene-therapy pressure

Biosimilar competition reduces price while HEMGENIX and BEQVEZ reduce the number of patients requiring chronic factor replacement. This is the most severe long-term downside scenario because it attacks both price and treatment volume.

Gene therapy will not eliminate factor replacement demand immediately. Patients with inadequate expression, waning response, contraindications, or access barriers may continue using ALPROLIX or another factor product.

What is the FDA regulatory status of ALPROLIX?

ALPROLIX is FDA approved and remains an established replacement therapy for hemophilia B. Its regulatory risk is lower than that of a newly launched biologic. The main regulatory and clinical risks relate to:

  • Inhibitor development
  • Hypersensitivity reactions
  • Thromboembolic events
  • Immunogenicity monitoring
  • Pediatric and long-term safety data
  • Manufacturing consistency
  • Post-market pharmacovigilance

The product’s established safety database supports continued use, but it does not protect against technological substitution by gene therapy or other factor IX platforms.

What is the outlook for ALPROLIX revenue?

ALPROLIX has a durable but declining-growth profile.

Near-term revenue support comes from the chronic nature of hemophilia B, physician familiarity, established reimbursement, and demand for extended-half-life prophylaxis. Downward pressure comes from gene therapy, competing extended-half-life products, price negotiations, biosimilar development, and reduced dosing frequency.

The most likely trajectory is stable-to-declining revenue rather than abrupt obsolescence. A sharp decline would require both successful gene-therapy adoption and effective biosimilar or price competition. Until those conditions converge, ALPROLIX should remain a material Sanofi rare-disease product with recurring cash flow.

Key Takeaways

  • ALPROLIX is an extended-half-life recombinant factor IX-Fc biologic for hemophilia B.
  • Bioverativ reported revenue growth from approximately $294 million in 2015 to $460 million in 2017.
  • Sanofi acquired Bioverativ for approximately $11.6 billion in 2018.
  • U.S. reference-product biologic exclusivity generally reaches its 12-year point in March 2026.
  • Paragraph IV litigation is not the primary challenge mechanism; biosimilar review and BPCIA litigation are the relevant frameworks.
  • The principal direct competitors are IDELVION and REBINYN.
  • HEMGENIX and BEQVEZ create the most important long-term substitution risk.
  • Manufacturing complexity and regulatory requirements support the product’s defensive position after patent and exclusivity loss.
  • The most probable commercial path is gradual erosion, with downside increasing if biosimilar entry overlaps with broad gene-therapy adoption.

FAQs

Is ALPROLIX a biosimilar or a reference biologic?

ALPROLIX is an original reference biologic approved under section 351(a) of the Public Health Service Act. It is not a biosimilar.

Can ALPROLIX be substituted automatically at the pharmacy?

Automatic substitution depends on FDA interchangeability status, state law, payer policy, and product-specific authorization. Biosimilarity alone does not create automatic substitution rights.

Does gene therapy replace ALPROLIX permanently?

Not in every patient. Gene therapy may reduce or eliminate factor use for some patients, but durability, eligibility, safety, reimbursement, and inadequate factor expression can preserve demand for ALPROLIX.

Which company owns the ALPROLIX commercial rights?

Sanofi is the principal commercial owner following its acquisition of Bioverativ. The underlying patent and license history may vary by jurisdiction and patent family.

Is ALPROLIX revenue exposed to biosimilar price erosion?

Yes. Exposure increases after the U.S. reference-product exclusivity period and any enforceable patent protections expire or are settled. Erosion will depend on the number of entrants, interchangeability, payer contracting, and gene-therapy uptake.

References

  1. U.S. Food and Drug Administration. (2014). ALPROLIX prescribing information.
  2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
  3. Sanofi. (2018). Sanofi completes acquisition of Bioverativ.
  4. Bioverativ, Inc. (2018). 2017 annual report. U.S. Securities and Exchange Commission.
  5. U.S. Food and Drug Administration. (2022). FDA approves first gene therapies for hemophilia B.
  6. U.S. Food and Drug Administration. (2024). FDA approves gene therapy for adults with hemophilia B.
  7. Biologics Price Competition and Innovation Act of 2009, 42 U.S.C. § 262.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.